CanniMed Therapeutics Inc (CMED) Insider Buys C$175,010.00 in Stock

CanniMed Therapeutics Inc (TSE:CMED) insider Saskworks Venture Fund Inc. bought 21,500 shares of CanniMed Therapeutics stock in a transaction dated Friday, July 7th. The shares were bought at an average cost of C$8.14 per share, with a total value of C$175,010.00.

Saskworks Venture Fund Inc. also recently made the following trade(s):

  • On Thursday, July 13th, Saskworks Venture Fund Inc. bought 126,500 shares of CanniMed Therapeutics stock. The shares were bought at an average cost of C$8.35 per share, with a total value of C$1,056,275.00.

CanniMed Therapeutics Inc (CMED) traded down 0.39% on Friday, reaching $10.30. The company had a trading volume of 32,566 shares. CanniMed Therapeutics Inc has a 12 month low of $7.32 and a 12 month high of $13.35. The stock’s market capitalization is $233.88 million. The firm has a 50 day moving average price of $9.30 and a 200-day moving average price of $10.54.

ILLEGAL ACTIVITY NOTICE: This report was reported by Community Financial News and is the property of of Community Financial News. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at

CanniMed Therapeutics Company Profile

CanniMed Therapeutics Inc is a Canada-based plant biopharmaceutical company. It is specialized in the production of pharmaceutical-grade cannabis and offers a range of pharmaceutical-grade cannabis products. In addition, the Company has a plant biotechnology research and product development program focused on the production of plant-based materials for pharmaceutical, agricultural and environmental applications.

What are top analysts saying about CanniMed Therapeutics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for CanniMed Therapeutics Inc and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit